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Cytokine production capacity in depression and anxiety
N Vogelzangs1,2, P de Jonge3, JH Smit2, S Bahn4 and BW Penninx2
Recent studies have suggested that immune function may be dysregulated in persons with depressive and anxiety disorders. Few
studies examined the expression of cytokines in response to ex vivo stimulation of blood by lipopolysaccharide (LPS) to study the
innate production capacity of cytokines in depression and anxiety. To investigate this, baseline data from the Netherlands Study of
Depression and Anxiety (NESDA) were used, including persons (18–65 years; 66% women) with current (that is, past month; N= 591)
or remitted (N= 354) DSM-IV depressive or anxiety disorders and healthy controls (N= 297). Depressive and anxiety symptoms were
measured by means of the Inventory of Depressive Symptomatology (IDS) and the Beck Anxiety Inventory (BAI). Using Multi-
Analyte Proﬁling technology, plasma levels of 13 cytokines were assayed after whole blood stimulation by addition of LPS. Basal
plasma levels of C-reactive protein, interleukin-6 and tumor necrosis factor-α were also available. A basal and a LPS summary index
were created. Results show that LPS-stimulated inﬂammation was associated with increased odds of current depressive/anxiety
disorders (odds ratio (OR) = 1.28, P= 0.009), as was the case for basal inﬂammation (OR= 1.28, P= 0.001). These associations were no
longer signiﬁcant after adjustment for lifestyle and health (OR = 1.13, P= 0.21; OR= 1.07, P= 0.45, respectively). After adjustment for
lifestyle and health, interleukin-8 was associated with both remitted (OR = 1.25, P= 0.02) and current (OR= 1.28, P= 0.005) disorders.
In addition, LPS-stimulated inﬂammation was associated with more severe depressive (β= 0.129, Po0.001) and anxiety (β= 0.165,
Po0.001) symptoms, as was basal inﬂammation. Unlike basal inﬂammation, LPS-stimulated inﬂammation was still associated with
(anxiety) symptom severity after adjustment for lifestyle and health (IDS: interleukin (IL)-8, MCP-1, MMP2; BAI: LPS index, IL-6, IL-8,
IL-10, IL-18, MCP-1, MMP2, TNF-β). To conclude, lifestyle and health factors may partly explain higher levels of basal, as well as
LPS-stimulated inﬂammation in persons with depressive and anxiety disorders. However, production capacity of several cytokines
was positively associated with severity of depressive and in particular anxiety symptoms, even while taking lifestyle and health
factors into account. Elevated IL-8 production capacity in both previously and currently depressed and anxious persons might
indicate a genetic vulnerability for these disorders.
Translational Psychiatry (2016) 6, e825; doi:10.1038/tp.2016.92; published online 31 May 2016
INTRODUCTION
Depression, as well as anxiety disorders are of major importance
for public health.1–3 These disorders are associated with a great
loss in quality of life,4 increased (cardiovascular) morbidity and
mortality,5–7 and show a high rate of recurrence and chronicity.8–10
Treatment of depression and anxiety disorders, including
the prevention of relapse, is only effective in about a third to a
half of patients.11,12 Nearly all available antidepressants, which
are also often prescribed for anxiety disorders, act by increasing
monoaminergic transmission, although the etiology of
depression and anxiety is much more diverse. Extensive knowl-
edge of other pathophysiological mechanisms is needed to guide
development of new treatments for depression and anxiety
disorders.
In the past decade, an increasing number of studies—as
summarized in meta-analyses—has indicated that inﬂammatory
marker levels such as C-reactive protein (CRP), interleukin (IL)-6
and tumor necrosis factor (TNF)-α are elevated in depressed
persons signifying immune dysregulation.13,14 Depression could
bring about disturbances in important stress systems of the
human body, that is, the hypothalamus–pituitary–adrenal axis15,16
and the autonomic nervous system,17,18 which in turn might
stimulate production of cytokines.19,20 On the other hand,
administration of pro-inﬂammatory cytokines (for instance in
cancer or hepatitis C treatment) has consistently been shown to
induce depressive symptoms in about a third of patients.21
Depression shows a high degree of comorbidity with anxiety
disorders,22 which suggests partly overlapping etiology. Some
recent studies show evidence that immune dysregulation also
plays a role in anxiety.23,24 Although many studies have focused
on depressive disorder or symptoms in general, increasing
evidence suggests it is important to take clinical characteristics
into account to delineate which depressed and anxious persons
show dysregulation of the immune system. Previously, we found
that in particular somatic symptoms of depression and anxiety, as
compared with cognitive symptoms, were associated with
inﬂammation.25 Also, we found inﬂammation levels to be elevated
in atypical depression, but not in melancholic depression.5,26
These ﬁndings are in line with the sickness behavior theory which
argues that somatic depressive-like symptoms such as fatigue,
sleeping problems, anorexia and motor slowing can be the result
of upregulated inﬂammation levels.27
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Although the theory of immune dysregulation in depression
and possibly anxiety is appealing, not all evidence is consistent.
One important aspect of earlier studies is that they have generally
assessed basal circulating levels of inﬂammatory markers, which
typically have low values, show a high degree of intra-individual
variability and which might be strongly inﬂuenced by lifestyle and
disease status. A meta-analysis by Howren et al.14 indicates that
the association between depression and inﬂammation is largely
weakened when taking body mass index (BMI) into account. The
expression of inﬂammatory markers in response to ex vivo
stimulation of blood by lipopolysaccharide (LPS) may give more
insight into the functioning of immune regulation.28 It mimics the
natural environment more closely and induces an inﬂammatory
reaction reﬂecting the innate production capacity of inﬂammatory
markers,29 which is known to be under strong genetic control.30 A
recent study suggests that the variability seen when assessing
basal levels, may be reduced by measuring inﬂammatory markers
in LPS-stimulated blood, as LPS-stimulated, but not basal,
inﬂammatory marker levels were found to be elevated in
Alzheimer’s disease patients.31 With respect to depression, only
one study showed that increased production of IL-1β and
decreased IL-1 receptor antagonist production, as measured after
LPS stimulation, preceded the development of depressive
symptoms in a sample of older persons.28 So, although promising,
up until now knowledge on whether LPS-stimulated cytokines,
and which in particular, are related to depression and anxiety is
rather lacking.
Considering all the above, the current study has four aims: to
examine whether innate cytokine production capacity is asso-
ciated with depressive and anxiety disorders (ﬁrst aim) and
symptom severity (second aim), also while considering the role of
lifestyle and health factors. The third aim of this study is to
investigate whether the innate cytokine production capacity is
speciﬁcally associated with particular depressive and anxiety
symptom subscales. We hypothesize to ﬁnd speciﬁc associations
with somatic, but not cognitive symptoms, and with atypical, but
not melancholic symptoms. Finally, as basal levels of CRP, IL-6 and
TNF-α are available, we are able to compare associations of basal
versus LPS-stimulated cytokine levels with depression and anxiety
within the same study sample (fourth aim). We expect more
robust associations for the LPS-stimulated markers compared with
the basal inﬂammation levels. We have no a priori hypothesis on
which LPS-stimulated cytokines will be upregulated in depression




The Netherlands Study of Depression and Anxiety (NESDA) is an ongoing
cohort study designed to investigate the long-term course and con-
sequences of depressive and anxiety disorders. Participants were 18–65
years old at baseline assessment in 2004–2007 and were recruited from
the community (19%), general practice (54%) and secondary mental health
care (27%). To maintain representativity, only two exclusion criteria existed:
(1) a primary clinical diagnosis of a psychiatric disorder not subject of
NESDA, which will largely affect course trajectory: psychotic disorder,
obsessive compulsive disorder, bipolar disorder or severe addiction
disorder, and (2) not being ﬂuent in Dutch since language problems
would harm the validity and reliability of collected data. A total of 2981
persons were included, consisting of persons with a current or past
depressive and/or anxiety disorder and healthy controls. A detailed
description of the NESDA study design and sampling procedures can be
found elsewhere.32 The research protocol was approved by the Ethical
Committee of participating universities and after complete description of
the study all respondents provided written informed consent.
Due to organizational reasons, LPS stimulation of blood was only
conducted at the last year of the baseline sample collection. Consequently,
data of LPS-stimulated inﬂammatory markers were available for a random
sample of 1242 persons, which constitute the sample of the present study.
Included persons did not differ from the remainder of NESDA respondents
(n=1739) in terms of sex and years of education, but were somewhat older
(42.8 (s.d. = 12.7) vs 41.2 (s.d. = 13.3) years, P= 0.001) and had slightly more
often no lifetime depressive or anxiety disorder (23.9% vs 20.4%, P= 0.02).
Depressive and anxiety disorders
During the baseline interview, lifetime presence of depressive disorder
(major depressive disorder, dysthymia) and anxiety disorder (social phobia,
generalized anxiety disorder, panic disorder, agoraphobia) was established
using the Composite Interview Diagnostic Instrument (CIDI) according to
DSM-IV criteria.33 The CIDI is a reliable and valid instrument for assessing
depressive and anxiety disorders34 and was administered by specially
trained research staff. Persons were grouped into ‘no depressive/anxiety
disorder’, ‘remitted depressive/anxiety disorder’ (that is, lifetime presence,
but not in the past month) and ‘current anxiety/depressive' disorder (that
is, in the past month). Current disorders were further categorized into
‘depressive disorder only’, ‘anxiety disorder only’, and ‘comorbid depres-
sive' and anxiety disorder’.
Depressive and anxiety symptom severity
The severity of depressive symptoms was measured using the 30-item self-
report Inventory of Depressive Symptomatology (IDS; range 0–84).35 The
IDS has been shown to have good psychometric properties with high
correlations between the IDS and the Hamilton Depression Rating Scale
and the Beck Depression Inventory-I (www.ids-qids.org). The severity of
anxiety symptoms was measured by means of the 21-item self-report Beck
Anxiety Inventory (BAI; range 0-63).36 The internal and test–retest reliability
and validity of the BAI are well-established.36,37 Individual items on the IDS
and BAI are rated from 0 to 3.
Depressive and anxiety symptom subscales
As we have previously found basal inﬂammation to be more speciﬁcally
associated with somatic symptoms than with cognitive symptoms,25 and
more with atypical depression than with melancholic depression,26 we a
priori created several symptom subscales. Previous research has shown
that the BAI consists of two subscales accounting for 84% of the variance,
that is, a somatic subscale and a cognitive subscale.38 The somatic subscale
consists of 14 items (Cronbach’s α= 0.90) and the cognitive subscale
consists of 7 items (Cronbach’s α= 0.88) (see Supplementary Table 1). A
somatic and a cognitive symptoms subscale were also derived from the
IDS, based on DSM-IV criteria and on previous research on somatic and
cognitive depressive symptoms,39,40 as used before.25 Both the somatic
and the cognitive subscale consisted of 10 items (see Supplementary Table
1). Because the sleep symptoms were overrepresented, we created a
variable combining the four sleep items by taking the mean score of all
four items. This resulted in Cronbach’s α= 0.79 for the somatic symptoms
subscale and Cronbach’s α= 0.90 for the cognitive symptoms subscale.
Based on the IDS, we also constructed an atypical and a melancholic
symptoms subscale, including all items corresponding to the DSM-IV
criteria for atypical and melancholic depression (see Supplementary Table
1; atypical symptoms scale: Cronbach’s α= 0.62; melancholic symptoms
scale: Cronbach’s α=0.77).
Inﬂammatory markers
Assaying of inﬂammatory markers was done by laboratory staff completely
blinded to the clinical status of the participants. Markers of basal
inﬂammation were assessed at baseline and included CRP, IL-6 and TNF-
α. Fasting blood samples of NESDA participants were obtained in the
morning around 0800 hours and kept frozen at − 80 °C. CRP and IL-6 were
assayed at the Clinical Chemistry department of the VU University Medical
Center. High-sensitivity plasma levels of CRP were measured in duplicate
by an in-house enzyme-linked immunosorbent assay (ELISA) based on
puriﬁed protein and polyclonal anti-CRP antibodies (Dako, Glostrup,
Denmark). Plasma IL-6 levels were measured in duplicate by a high-
sensitivity ELISA (PeliKine Compact ELISA, Sanquin, Amsterdam, the
Netherlands). Plasma TNF-α levels were assayed in duplicate at Good
Biomarker Science, Leiden, the Netherlands, using a high-sensitivity solid
phase ELISA (Quantikine HS Human TNF-α Immunoassay, R&D Systems,
Minneapolis, MN, USA). Intra- and inter-assay coefﬁcients of variation were
5 and 10% for CRP, 8 and 12% for IL-6, and 10 and 15% for TNF-α.
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Distributions of CRP, IL-6 and TNF-α values were skewed to the right and
therefore were ln-transformed to successfully normalize distributions.
To reﬂect the innate production capacity of inﬂammatory markers, the
innate immune response of 17 cytokines was assessed in blood that was
ex vivo stimulated with LPS. Serial venous whole blood samples were
obtained at baseline in one 7-ml heparin-coated tube (Greiner Bio-one,
Monroe, NC, USA). Between 10 and 60 min after blood draw, 2.5 ml of
blood was transferred into a PAXgen tube (Qiagen, Valencia, CA, USA).
Remaining blood (4.5 ml) was stimulated by addition of LPS (10 ng ml− 1
blood; Escherichia coli, Sigma, St. Louis, MO, USA), as done by others.28,31
LPS-stimulated samples were laid ﬂat and incubated at a slow rotation for
5–6 h at 37 °C. A 2.5-ml sample of this LPS-stimulated blood was
transferred into a PAXgene tube. This LPS procedure was carried out at
four laboratories (Amsterdam, Leiden, Groningen, Heerenveen). Remaining
plasma (±0.5 ml) was kept frozen at − 80 °C for later assaying. Levels of
granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon
(IFN)-γ, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-18, monocyte chemotactic
protein-1 (MCP-1), macrophage inﬂammatory protein (MIP)-1α, MIP-1β,
matrix metalloproteinase-2 (MMP2), TNF-α and TNF-β were assayed
simultaneously for all available samples, using a multi-analyte proﬁle
(Human CytokineMAP A v 1.0; Myriad RBM, Austin, TX, USA). This
commercial platform adheres to stringent guidelines of quality control
and has Clinical Laboratory Improvement Amendments (CLIA) approval,
which means that the platform is validated and calibrated on a continuous
basis.41 For GM-CSF, IL-3, IL-5 and IL-7 too little valid values were obtained
(valid no200) and were therefore excluded from further analyses, leaving
a total of 13 cytokines. With the exception of MMP2 and TNF-β (which
showed a normal distribution), all cytokines were skewed to the right and
therefore were ln-transformed to successfully normalize distributions.
As we did not have speciﬁc hypotheses about individual inﬂammation
markers, and rather sought to examine a general increased level of
cytokine production capacity, we created an LPS-stimulated inﬂammation
index, as well as a basal inﬂammation index. This also allowed us to better
compare basal inﬂammation versus LPS-stimulated inﬂammation and to
reduce the number of main analyses. A basal inﬂammation index was
calculated as the standardized sum of all 3 ln-transformed (that is, normally
distributed) standardized basal inﬂammation markers and an LPS-
stimulated inﬂammation index was calculated as the standardized sum
of all 13 (normally distributed) standardized LPS-stimulated inﬂammation
markers. Standardization was based on the grand mean (s.d.) of each
marker (that is, N= 1242). Both inﬂammation indexes are considered the
main inﬂammation variables of interest. For the most important analyses,
individual inﬂammation markers are also analyzed and presented in a
supplement to test consistency across markers.
Covariates
Sociodemographic characteristics included sex and age. Several lifestyle
and health characteristics were assessed as these can be associated with
both psychopathology and inﬂammation. Smoking status (never, former,
current) was self-reported. Alcohol intake was classiﬁed as o1, 1–14/1–21
(women/men) and 414/21 (women/men) drinks per week; based on
general guidelines that are used in health organizations in the
Netherlands42 and as used in other studies.43 Physical activity was
measured with the International Physical Activity Questionnaire44 in
MET-minutes (ratio of energy expenditure during activity compared with
rest times the number of minutes performing the activity) per week.
BMI was calculated as weight in kilograms divided by height in
meters squared. The number of self-reported chronic diseases for which
persons received treatment (including heart disease, diabetes, stroke, lung
disease, osteoarthritis or rheumatic disease, cancer, ulcer, intestinal
problem, liver disease, epilepsy and thyroid gland disease) was counted.
Medication use was assessed based on drug container inspection of all
drugs used in the past month and classiﬁed according to the World Health
Organization Anatomical Therapeutic Chemical classiﬁcation.45 Use of
systemic anti-inﬂammatory medication included ATC codes M01A, M01B,
A07EB and A07EC. In addition, regular antidepressant medication use
included selective serotonin reuptake inhibitors (N06AB), serotonin–
norepinephrine reuptake inhibitors (N06AX16, N06AX21), tricyclic anti-
depressants (N06AA) and tetracyclic antidepressants (N06AX03, N06AX05,
N06AX11).
Statistical analyses
Baseline characteristics across disorder status (no, remitted, current) were
compared using Χ2-tests for dichotomous and categorical variables and one-
way analysis of variance (ANOVA) for normally distributed continuous
variables. For descriptive purposes, all inﬂammatory markers are presented
untransformed, though the P-values are based on one-way ANOVA of the
normally distributed ln-transformed values. Pearson r correlations were
estimated between all individual inﬂammatory markers and the basal and
LPS-stimulated inﬂammation indexes. Associations of covariates with the
basal inﬂammation index and the LPS-stimulated inﬂammation index were
assessed using one-way ANOVA for dichotomous and categorical variables
and Pearson r correlations for continuous variables. Associations of
inﬂammation with depressive/anxiety disorder status and symptom severity
were tested using multinomial logistic and linear regression analyses,
adjusted for laboratory site, sex and age. Lifestyle and health factors may
be part of the mechanism relating inﬂammation to depression/anxiety, which
might especially be the case for BMI and chronic diseases, but could also be
genuine confounding factors. Therefore, to avoid over-correction, but to still
be able to check whether found associations are dependent on lifestyle and
health characteristics, associations were additionally adjusted for smoking and
alcohol intake and in a separate step additionally for BMI and number of
chronic diseases. Last, linear regression analyses were performed assessing
the association between the basal inﬂammation index and the LPS-stimulated
inﬂammation index with the different symptom subscales (IDS somatic, IDS
cognitive, BAI somatic, BAI cognitive, IDS atypical, IDS melancholic).
RESULTS
Sample description
Mean age of the study sample was 42.8 (s.d. = 12.7) years and 65.7%
were women. Table 1 compares baseline characteristics across
persons without a depressive or anxiety disorder (n=297), with a
history of an anxiety or depressive disorder (n=354) and with a
current (that is, in the past month) depressive or anxiety disorder
(n=591; including 536 persons fulﬁlling complete diagnostic criteria
in the past 2 weeks). Over the past 4.5 years, persons with a current
disorder reported symptoms 58% (s.d. = 35) of the time, corre-
sponding to a median of 30 (interquartile range (IQR) = 14–52)
months. From the 354 remitted persons, 103 remitted from their
depressive/anxiety disorder between 1 and 6 months ago, 28
between 6 months and 1 year ago, and 223 more than 1 year ago.
Persons with a remitted disorder were somewhat older compared
with the other groups. Persons with a current disorder were more
often non-drinker, less physically active and had more chronic
diseases than persons without depressive/anxiety disorder. Persons
with a remitted or current disorder were also more often current
smoker, tended to have a higher BMI and more often used anti-
inﬂammatory medication compared with controls. Most basal, as
well as LPS-stimulated inﬂammatory levels were highest among
those with a current disorder.
Inﬂammatory marker correlates
Pearson’s correlations (see Supplementary Table 2) between basal
inﬂammatory markers were small (0.1–0.3), while LPS-stimulated
inﬂammatory markers in general correlated much stronger (0.4–
0.9, with some exceptions for IL-4 and IL-10). These moderate to
strong correlations underline our strategy of adding standardized
values to obtain the LPS-stimulated inﬂammation index. The
Pearson’s correlation between the basal inﬂammation index and
the LPS-stimulated inﬂammation index was small (r= 0.13,
Po0.001), suggesting that these are two distinct indicators of
immune regulation. The associations of covariates with the basal
and LPS-stimulated inﬂammation indexes are shown in Table 2.
Sex was associated with the LPS-stimulated inﬂammation index
(higher in men), but not the basal inﬂammation index, while
alcohol intake, anti-inﬂammatory medication use and antidepres-
sant medication use were positively associated with the basal
inﬂammation index only. Higher age and current smoking similarly
increased basal and LPS-stimulated inﬂammatory levels, while the
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size of association of BMI and the number of chronic disease was
somewhat stronger with the basal inﬂammation index than with
the LPS-stimulated inﬂammation index. Physical activity was
associated with neither index.
Inﬂammation and depressive/anxiety disorders
Table 3 shows the associations between the basal and LPS-
stimulated inﬂammation indexes with remitted and current
depressive and anxiety disorders after adjustment for site, sex and
age. The basal inﬂammation index, as well as the LPS-stimulated
inﬂammation index were not associated with a remitted disorder,
but signiﬁcantly increased the odds of a current depressive/anxiety
disorder. The ORs of both the basal and the LPS-stimulated
inﬂammation index were of similar size (both OR=1.28), also when
including both indexes in one model (OR=1.25 and OR=1.20,
respectively), suggesting independent effects of basal inﬂammation
levels and LPS-stimulated inﬂammation levels on disorder status.
Table 1. Baseline characteristics according to depressive/anxiety disorder status
No









Demographics, lifestyle and health
Women, % 62.0 66.4 67.2 0.29
Age (years), mean (s.d.) 42.2 (13.9) 44.2 (12.5) 42.2 (12.1) 0.04
Smoking status, % o0.001
Never smoker 37.7 26.0 26.2
Former smoker 38.7 36.7 29.9
Current smoker 23.6 37.3 43.8
Alcohol intake, % o0.001
None 21.2 25.4 40.1
Moderate 66.7 64.4 47.5
Heavy 12.1 10.2 12.4
Physical activity (1000 MET-min), mean (s.d.) 4.0 (3.1) 3.8 (2.9) 3.5 (3.0) 0.04
Body mass index, mean (s.d.) 25.2 (4.7) 25.7 (4.8) 25.9 (5.3) 0.14
Number of chronic diseases, mean (s.d.) 0.5 (0.7) 0.6 (0.8) 0.8 (1.0) o0.001
Anti-inﬂammatory medication use, % 2.0 7.1 5.6 0.01
Clinical characteristics
Current disorder status, % NA
Pure depressive disorder NA NA 22.0
Pure anxiety disorder NA NA 37.1
Comorbid depressive/anxiety disorder NA NA 40.9
Depression severity (IDS), mean (s.d.) 7.2 (6.8) 15.8 (10.0) 31.0 (12.5) o0.001
IDS somatic score, mean (s.d.) 2.2 (2.3) 4.3 (3.1) 7.9 (3.9) o0.001
IDS cognitive score, mean (s.d.) 1.7 (2.6) 5.0 (4.4) 11.7 (5.9) o0.001
IDS atypical score, mean (s.d.) 1.3 (1.6) 2.6 (2.0) 4.7 (2.8) o0.001
IDS melancholic score, mean (s.d.) 1.4 (2.2) 3.6 (3.6) 8.2 (4.6) o0.001
Anxiety severity (BAI), mean (s.d.) 3.2 (4.4) 8.3 (7.3) 18.3 (10.8) o0.001
BAI somatic score, mean (s.d.) 2.1 (3.0) 5.2 (5.1) 10.8 (7.3) o0.001
BAI cognitive score, mean (s.d.) 1.1 (1.8) 3.1 (3.0) 7.5 (4.6) o0.001
Basal inﬂammatory markers
CRP (mg l− 1), median (IQR)b 1.08 (0.51–2.37) 1.22 (0.54–2.74) 1.34 (0.60–3.47) 0.01
IL-6 (pg ml− 1), median (IQR)b 0.71 (0.50–1.20) 0.73 (0.47–1.25) 0.85 (0.54–1.44) 0.01
TNF-α (pg ml− 1), median (IQR)b 0.70 (0.60–1.10) 0.80 (0.60–1.10) 0.80 (0.60–1.10) 0.42
Basal inﬂammation index, mean (s.d.) − 0.13 (0.90) − 0.06 (1.00) 0.10 (1.03) 0.002
LPS-stimulated inﬂammatory markers
IFN-γ (pg ml− 1), median (IQR)b 9.8 (6.5–15.7) 9.7 (6.5–13.9) 10.2 (7.4–14.5) 0.15
IL-2 (pg ml− 1), median (IQR)b 8.0 (5.6–11.5) 8.4 (5.6–12.2) 9.1 (6.2–13.3) 0.04
IL-4 (pg ml− 1), median (IQR)b 8.2 (4.0–13.4) 9.0 (4.1–15.9) 9.0 (4.4–14.1) 0.13
IL-6 (ng ml− 1), median (IQR)b 25.2 (15.5–35.8) 24.2 (15.9–33.5) 26.9 (18.3–36.1) 0.01
IL-8 (ng ml− 1), median (IQR)b 9.1 (5.8–13.4) 10.5 (6.6–15.6) 11.1 (7.6–16.4) o0.001
IL-10 (pg ml− 1), median (IQR)b 205 (98–374) 200 (112–383) 206 (115–406) 0.12
IL-18 (pg ml− 1), median (IQR)b 241 (193–286) 248 (196–298) 254 (210–317) 0.001
MCP-1 (ng ml− 1), median (IQR)b 1.4 (0.9–2.1) 1.3 (0.8–2.2) 1.6 (1.1–2.4) o0.001
MIP-1α (ng ml− 1), median (IQR)b 17.2 (11.3–25.0) 17.0 (10.8–23.9) 18.6 (12.4–25.5) 0.006
MIP-1β (ng ml− 1), median (IQR)b 219 (151–299) 228 (159–305) 241 (170–320) 0.003
MMP2 (ng ml− 1), mean (s.d.) 69.4 (19.5) 70.4 (20.5) 74.1 (18.8) 0.001
TNF-α (ng ml− 1), median (IQR)b 2.8 (1.8–4.2) 2.8 (1.8–4.1) 2.8 (1.9–4.1) 0.59
TNF-β (pg ml− 1), mean (s.d.) 299 (135) 305 (140) 328 (133) 0.003
LPS-stimulated inﬂammation index, mean (s.d.) − 0.13 (1.06) − 0.07 (1.08) 0.11 (0.90) 0.001
Abbreviations: ANOVA, analysis of variance; BAI, Beck Anxiety Inventory; CRP, C-reactive protein; IDS, Inventory of Depressive Symptomatology; IFN, interferon;
IL, interleukin; IQR, interquartile range; LPS, lipopolysaccharide; MCP, monocyte chemotactic protein; MIP, macrophage inﬂammatory protein; MMP, matrix
metalloproteinase; NA, not applicable; TNF, tumor necrosis factor. aP-values based on Χ2-test for dichotomous and categorical variables and one-way ANOVA
for continuous variables. bMedian (IQR) is presented because variable is non-normally distributed; however, P-values are based on one-way ANOVA of the
normally distributed ln-transformed values.
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When excluding all persons with a chronic disease (that is, heart
disease, diabetes, lung disease, osteoarthritis or rheumatic disease,
cancer, intestinal problems; n excluded = 260), results remained
similar (separate models: basal index-current disorder: OR = 1.30;
LPS index-current disorder: OR = 1.24). When adjusting the basic
analyses on disorder status for depressive and anxiety symptoms
(IDS and BAI, respectively), ORs decreased somewhat and were no
longer signiﬁcant, suggesting there is no independent effect of
Table 2. Associations of baseline characteristics with inﬂammation indexes
Basal index LPS index
N Mean (s.d.) or r Pa Mean (s.d.) or r Pa
Sex 0.59 o0.001
Men 426 0.02 (1.00) 0.25 (1.03)
Women 816 − 0.01 (1.00) − 0.13 (0.96)
Age 1242 0.16 o0.001 0.13 o0.001
Smoking status
Never smoker 359 − 0.05 (1.00) Ref − 0.13 (1.00) Ref
Former smoker 422 − 0.11 (0.99) 0.36 − 0.04 (0.98) 0.21
Current smoker 461 0.14 (1.00) 0.007 0.15 (1.00) o0.001
Alcohol intake
None 390 0.26 (1.06) Ref − 0.02 (0.99) Ref
Moderate 707 − 0.15 (0.95) o0.001 − 0.01 (0.99) 0.85
Heavy 145 0.03 (0.92) 0.02 0.07 (1.08) 0.37
Physical activity 1242 − 0.01 0.71 0.00 0.91
Body mass index 1242 0.40 o0.001 0.14 o0.001
Number of chronic diseases 1242 0.20 o0.001 0.13 o0.001
Anti-inﬂammatory medication 0.03 0.69
No 1178 − 0.01 (1.00) 0.00 (1.01)
Yes 64 0.27 (0.93) 0.05 (0.82)
Antidepressant medication o0.001 0.18
No 947 − 0.07 (0.98) − 0.03 (1.01)
SSRI 199 0.15 (1.05) 0.09 (0.97)
SNRI 43 0.28 (0.90) 0.03 (1.04)
TCA/TeCA 53 0.41 (1.06) 0.20 (0.79)
Abbreviations: ANOVA, analysis of variance; LPS, lipopolysaccharide; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake
inhibitor; TCA, tricyclic antidepressant; TeCA, tetracyclic antidepressant. aBased on one-way ANOVA for dichotomous and categorical variables and Pearson’s r
for continuous variables.
Table 3. Associationsa of inﬂammation indexes with depressive/anxiety disorder and severity
Remitted disorder
vs no disorder
N= 354 vs N=297
Current disorder
vs no disorder






N OR 95%CI P OR 95%CI P β P β P
Basal inﬂammation index
Basicb 1231 1.07 0.91–1.25 0.44 1.28 1.10–1.48 0.001 0.136 o0.001 0.111 o0.001
Lifestylec 1231 1.01 0.85–1.19 0.94 1.12 0.96–1.31 0.15 0.071 0.01 0.047 0.10
Healthd 1231 0.97 0.81–1.16 0.72 1.07 0.90–1.26 0.45 0.027 0.37 0.006 0.84
LPS-stimulated inﬂammation index
Basicb 1241 1.12 0.92–1.36 0.27 1.28 1.06–1.54 0.009 0.129 o0.001 0.165 o0.001
Lifestylec 1241 1.08 0.88–1.32 0.47 1.19 0.98–1.44 0.08 0.095 0.008 0.128 o0.001
Healthd 1241 1.06 0.86–1.30 0.60 1.13 0.93–1.38 0.21 0.060 0.09 0.099 0.005
Basal and LPS index in one model (basic adjustment)b
Basal 1231 1.05 0.90–1.24 0.53 1.25 1.08–1.45 0.004 0.122 o0.001 0.091 0.002
LPS 1231 1.10 0.90–1.35 0.44 1.20 0.99–1.45 0.06 0.103 0.006 0.145 o0.001
Abbreviations: BAI, Beck Anxiety Inventory; CI, conﬁdence interval; IDS, Inventory of Depressive Symptomatology; LPS, lipopolysaccharide; OR, odds ratio.
aBased on multinomial logistic regression analyses with disorder status as outcome (no lifetime disorder= reference group) and on linear regression analyses
with severity as outcome. bBasic= adjusted for site, sex and age. cLifestyle=basic+adjusted for current smoking and alcohol intake. dHealth= lifestyle
+adjusted for body mass index and number of chronic diseases.
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disorder status apart from symptom severity. To assess possible
differential effects for depressive versus anxiety disorders, current
disorders were stratiﬁed into pure depressive disorder (n= 130),
pure anxiety disorder (n= 219) and comorbid disorder (n= 242)
and compared with controls in one multinomial logistic regression
analysis, but results were rather similar across these three
categories (basal index: OR = 1.26, OR= 1.18, OR= 1.38; LPS index:
OR= 1.33, OR= 1.26, OR= 1.27).
Table 3 also presents results after additional adjustment for
lifestyle (current smoking, alcohol intake) and further health
factors (BMI, number of chronic diseases). After these adjustments,
both indexes were no longer signiﬁcantly associated with a
current disorder.
Associations of individual inﬂammation markers with depres-
sive/anxiety disorder are shown in Supplementary Table 3. After
basic adjustment, higher basal levels of CRP and IL-6 were
associated with the presence of current depressive/anxiety
disorder. Also, several individual LPS-stimulated inﬂammation
markers showed an increased OR for current disorder, which was
signiﬁcant for IL-8, IL-18, MCP-1, MIP-1β, MMP2 and TNF-β. IL-4
and IL-8 were (also) associated with a remitted depressive/anxiety
disorder. To assess whether associations were independent of
lifestyle and health factors, signiﬁcant markers were additionally
adjusted for current smoking, alcohol intake, BMI and number of
chronic diseases (results not tabulated). Associations turned to
non-signiﬁcant, except for IL-8, which was still signiﬁcantly
associated with both remitted (OR = 1.25, 95%CI = 1.04–1.49,
P= 0.02) and current (OR = 1.28, 95%CI = 1.08–1.52, P= 0.005)
depressive/anxiety disorders. This ﬁnding remained similar after
additional adjustment for physical activity and anti-inﬂammatory
medication.
Inﬂammation and depressive/anxiety symptom severity
Table 3 also shows the associations between the inﬂammation
indexes and depressive (IDS) and anxiety (BAI) symptom severity
after adjustment for site, sex and age. The basal inﬂammation
index, as well as the LPS-stimulated inﬂammation index were
signiﬁcantly associated with both depressive and anxiety symp-
tom severity. Even when including both indexes in one model, the
basal and LPS-stimulated inﬂammation indexes both remained
signiﬁcant and were rather comparable in effect size for
depressive symptom severity (β= 0.122 and β= 0.103, respec-
tively), suggesting independent associations. For anxiety severity,
when including the basal and LPS-stimulated inﬂammation
indexes in the same model, the association of the LPS-
stimulated inﬂammation index was somewhat larger than the
association of the basal inﬂammation index (β= 0.145 and
β= 0.091, respectively), although both were signiﬁcant.
When excluding all persons with a chronic disease (that is, heart
disease, diabetes, lung disease, osteoarthritis or rheumatic disease,
cancer, intestinal problems; n excluded = 260), associations
decreased somewhat but were still signiﬁcant (basal index: IDS:
β= 0.098, P= 0.003; BAI: β= 0.071, P= 0.03; LPS index: IDS:
β= 0.108, P= 0.01; BAI: β= 0.134, P= 0.001). Also, when addition-
ally adjusting the basic analyses for depressive/anxiety disorder
status, associations decreased somewhat but were still signiﬁcant
(basal index: IDS: β= 0.067, P= 0.002; BAI: β= 0.052, P= 0.03; LPS
index: IDS: β= 0.063, P= 0.02; BAI: β= 0.109, Po0.001). Due to a
high correlation between IDS and BAI (Pearson’s r= 0.80),
depressive and anxiety symptom analyses could not be adjusted
for each other.
Table 3 also presents results after additional adjustment for
lifestyle (current smoking, alcohol intake) and further health
factors (BMI, number of chronic diseases). Both the basal and LPS-
stimulated inﬂammation indexes were associated with depressive
symptom severity after lifestyle adjustment, but no longer after
further health adjustment. In contrast, the basal inﬂammation
index was already no longer associated with anxiety symptoms
after lifestyle adjustment, while the LPS-stimulated inﬂammation
index was still signiﬁcantly associated with anxiety symptoms after
both lifestyle and further health adjustment (β= 0.099, P= 0.005).
This ﬁnding remained similar after additional adjustment for
physical activity and anti-inﬂammatory medication.
Associations of individual inﬂammation markers with symptom
severity are shown in Supplementary Table 3. Basal CRP, IL-6 and
TNF-α, as well as most individual LPS-stimulated inﬂammation
markers (IL-6, IL-8, IL-10, IL-18, MCP-1, MIP-1α, MIP-1β, MMP2 and
TNF-β) were signiﬁcantly associated with depressive and anxiety
symptom severity. To check whether found associations were
dependent on lifestyle and health factors, analyses were
additionally adjusted for current smoking, alcohol intake, BMI
and number of chronic diseases (results not tabulated). No
associations remained for the basal inﬂammation markers.
However, with respect to LPS-stimulated inﬂammation markers,
associations remained signiﬁcant for IL-8 (β= 0.075, P= 0.01),
MCP-1 (β= 0.097, P= 0.003) and MMP2 (β= 0.083, P= 0.008) with
depressive symptom severity, and for IL-6 (β= 0.081, P= 0.02), IL-8
(β= 0.073, P= 0.02), IL-10 (β= 0.083, P= 0.02), IL-18 (β= 0.067,
P= 0.03), MCP-1 (β= 0.099, P= 0.003), MMP2 (β= 0.124, Po0.001)
and TNF-β (β= 0.105, P= 0.001) with anxiety symptom severity.
Results remained similar after additional adjustment for physical
activity and anti-inﬂammatory medication.
Table 4. Associationsa of inﬂammatory indexes with symptom subscales (N= 1242)
IDS somatic IDS cognitive BAI somatic BAI cognitive IDS atypical IDS melancholic
β P β P β P β P β P β P
Basal inﬂammation index
Basicb 0.153 o0.001 0.094 0.001 0.127 o0.001 0.064 0.03 0.136 o0.001 0.090 0.002
Lifestylec 0.095 0.001 0.036 0.22 0.067 0.02 0.008 0.77 0.086 0.003 0.033 0.26
Healthd 0.037 0.22 − 0.001 0.98 0.019 0.52 −0.015 0.63 0.010 0.75 0.010 0.75
LPS-stimulated inﬂammation index
Basicb 0.131 o0.001 0.113 0.002 0.169 o0.001 0.132 o0.001 0.098 0.007 0.102 0.006
Lifestylec 0.099 0.006 0.085 0.02 0.133 o0.001 0.101 0.005 0.074 0.04 0.069 0.06
Healthd 0.057 0.11 0.059 0.10 0.098 0.005 0.085 0.02 0.025 0.47 0.049 0.18
Abbreviations: BAI, Beck Anxiety Inventory; IDS, Inventory of Depressive Symptomatology; LPS, lipopolysaccharide aBased on linear regression analyses
with symptom proﬁle scores as outcome. bBasic= adjusted for site, sex and age. cLifestyle=basic+adjusted for current smoking and alcohol intake.
dHealth= lifestyle+adjusted for body mass index and number of chronic diseases.
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Inﬂammation and depressive/anxiety symptom subscales
Table 4 shows associations between the basal and LPS-stimulated
inﬂammation indexes and several depressive and anxiety symp-
tom subscales. After basic adjustment, both indexes were
signiﬁcantly associated with all subscales. After lifestyle adjust-
ment (current smoking, alcohol intake), in line with our earlier
ﬁndings,25,26 the basal inﬂammation index was associated with
somatic depressive, somatic anxiety and atypical symptoms, but
not with cognitive depressive, cognitive anxiety and melancholic
symptoms. In contrast, the LPS-stimulated inﬂammation index was
associated with somatic, as well as with cognitive depressive and
anxiety symptoms. Also, after lifestyle adjustment, the association
between the LPS-stimulated inﬂammation index with atypical and
melancholic symptoms was of equal size, although statistically
signiﬁcant for the former and only a trend ﬁnding for the latter
(β= 0.074, P= 0.04; β= 0.069, P= 0.06, respectively). After further
adjustment for BMI and number of chronic diseases, associations
weakened and were no longer signiﬁcant for the basal inﬂamma-
tion index. The LPS-stimulated inﬂammation index was still
signiﬁcantly associated with somatic (β= 0.098, P= 0.005), as well
as cognitive (β= 0.085, P= 0.02) anxiety symptoms.
DISCUSSION
This study examined innate cytokine production capacity in a
large sample of persons with varying levels of depression and
anxiety. Lifestyle and health factors may partly explain higher
levels of basal, as well as LPS-stimulated inﬂammation in persons
with depressive and anxiety disorders. However, we found that
cytokine production capacity was positively associated with
severity of depressive and in particular anxiety symptoms, even
while taking lifestyle and health factors into account. Elevated IL-8
production capacity in both previously and currently depressed
and anxious persons might indicate a genetic vulnerability for
these disorders.
In the present study, we were able to compare associations of
basal inﬂammation and cytokine production capacity in relation to
depression and anxiety within the same study sample. Our results
underline the idea that basal inﬂammation levels and stimulated
inﬂammation levels tap on two different aspects of the immune
system. The correlation between both concepts was rather low
and associations of basal and stimulated levels with depression/
anxiety seemed rather independent of each other, shown when
including both inﬂammation indexes in one model. Possibly, part
of this low correlation may be explained by the use of two
different distinct methods that were used to assess the basal
(ELISA) versus LPS-stimulated (multiplex) inﬂammation markers.
However, we also found differences in associations with covari-
ates. Basal inﬂammation appeared to be more strongly correlated
to several lifestyle and health factors, such as alcohol intake, BMI,
chronic diseases and medication use. In line with this, we found
that associations between basal inﬂammation and depression/
anxiety largely disappeared after adjustment for lifestyle and
health factors. Although associations between LPS-stimulated
inﬂammation levels and depression/anxiety also weakened after
lifestyle and health adjustment, especially with respect to disorder
status, several associations still remained (that is, IL-8 with
remitted and current disorder, IL-8, MCP-1 and MMP2 with
depressive symptom severity, and LPS-stimulated inﬂammation
index, IL-6, IL-8, IL-10, IL-18, MCP-1, MMP2 and TNF-β with anxiety
symptom severity). Prior research suggests a large role for BMI in
the association between inﬂammation and depression.14 Our
results suggest that this may even be more true for basal
inﬂammation levels, which are highly variable. Furthermore, we
and others have previously shown that antidepressant use might
affect basal inﬂammation levels.46–48 Our current ﬁndings suggest
that LPS-stimulated inﬂammation levels are less inﬂuenced by
antidepressant use.
Our study found no difference in associations of the innate
cytokine production capacity with depressive disorder versus
anxiety disorder. Our results also showed associations of cytokine
production capacity with both depressive and anxiety symptoms,
before and after adjustment for current smoking and alcohol
intake. However, after further adjustment for BMI and number of
chronic diseases, LPS-stimulated inﬂammation was more consis-
tently associated with anxiety symptoms (index and IL-6, IL-8,
IL-10, IL-18, MCP-1, MMP2, TNF-β) than with depressive symptoms
(IL-8, MCP-1, MMP2, but not the index). The relationship between
inﬂammation and anxiety has been much less studied than the
relationship with depression, but our results might suggest that
cytokine production capacity, rather than basal inﬂammation is
involved in anxiety. Future research should further investigate
these explorative ﬁndings.
Innate cytokine production capacity was equally associated with
cognitive and with somatic symptoms of depression and anxiety.
Similarly, cytokine production capacity was to the same degree
associated with melancholic and with atypical symptoms. In
contrast, after lifestyle adjustment basal inﬂammation levels, in
line with previous research,5,25,26 were in particular associated
with somatic symptoms and with atypical symptoms, but not with
cognitive and melancholic symptoms. This again underlines the
differences between the two inﬂammation measures and suggests
that innate cytokine production capacity might be generally
involved in depression and anxiety, while basal inﬂammation is
particularly important for depression and anxiety in which somatic
health plays an important role. Of note is that one of the most
important aspects of atypical depression is increased weight and
appetite which would clearly affect somatic health as well.
Interestingly, after additional adjustment for BMI and chronic
diseases, the differential association of basal inﬂammation with
somatic/atypical versus cognitive/melancholic symptoms
disappeared.
Although we found signiﬁcant associations for several speciﬁc
LPS-stimulated inﬂammation markers with depression and in
particular anxiety severity, the overall trend was increased levels of
all markers, as also indicated by the LPS-stimulated inﬂammation
index. At a closer look, this means that not only pro-inﬂammatory
cytokines were positively associated with symptom severity, but
also IL-10, which is an anti-inﬂammatory cytokine. This suggests
that it is exactly the innate cytokine production capacity which is
increased in depression and anxiety, regardless whether the
response is pro- or anti-inﬂammatory. This is in contrast, however,
with the study by van den Biggelaar,28 which found no association
between IL-10 and the onset of depressive symptoms, and found
a negative association between IL-1 receptor antagonist, also an
anti-inﬂammatory agent, and the onset of depressive symptoms.
Possibly, differences in design (cross-sectional versus longitudinal)
and in sample (adults versus elderly) can explain these differences.
Innate cytokine production capacity was associated with both
disorder status and symptom severity after basic adjustment. Due
to the high overlap between these constructs (that is, current
depressed/anxious persons score higher on IDS and BAI scales), it
is difﬁcult to determine independency of these associations. When
adjusting disorder status for symptom severity, signiﬁcances of
associations were lost. On the other hand, the LPS-stimulated
inﬂammation index was still signiﬁcantly associated with both
depression and anxiety severity after adjustment for disorder
status. Furthermore, more individual markers were associated with
(anxiety) severity than with disorder status and, unlike disorder
status, most associations with (anxiety) severity remained
signiﬁcant after lifestyle and health adjustment. It is, however,
too tentative to conclude whether innate cytokine production
capacity is an underlying trait which linearly increases the risk for
having more depressive and anxiety symptoms or whether it is
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especially associated with disorder status. In particular, IL-8 was
profoundly associated with disorder status, in the same degree to
remitted as to current disorders, even after adjustment for several
lifestyle and health factors. This might suggest a possible (genetic)
vulnerability and is in line with previous ﬁndings showing that
maternal IL-8 increases schizophrenia risk in offspring.49 Future
research should further investigate the role of IL-8 in depression
and anxiety.
Some limitations of our study need to be acknowledged. First,
our study had a cross-sectional design, which makes it impossible
to draw any conclusions about causality. However, the innate
cytokine production capacity, as measured via LPS-stimulated
inﬂammation levels, has been shown to be under strong genetic
control. Heritability estimates of the production capacity of various
cytokines range from 53 to 86% in non-diseased populations.30,50
This could indicate that cytokine production capacity is more likely
to be a causal factor than the consequence of depression or
anxiety. However, longitudinal studies are needed to investigate
this more thoroughly. Another limitation is that data on the innate
cytokine production capacity were only available in about 40% of
the total NESDA sample. However, the sample size was still quite
large and the sample was random. Included participants were
rather comparable on baseline characteristics compared with the
remainder of the NESDA participants. Furthermore, since we
excluded persons with severe mental disorders, our results might
not be generalizable to the subgroup of depressed and anxious
persons which have a severe comorbid mental disorder.
Speciﬁcally the exclusion of bipolar disorder could have impacted
our results. Bipolar disorder has also been associated with
inﬂammation.51,52 Our results show that depression and anxiety
are associated with inﬂammation even without the presence of
bipolar disorder. Furthermore, since persons with depressive and
anxiety disorders across different settings and developmental
stages were included, our result should be generalizable to the
greater part of depressed and anxious persons. Another limitation
is that symptom severity was based on self-report and not
clinically rated. Last, due to the high correlations between
depressive and anxiety symptoms and between disorder status
and symptom severity, we were not able to include these
outcomes in a single analysis to directly compare the magnitude
of associations of inﬂammation with these factors. Nonetheless,
our study also had some important strengths. This study was
among the ﬁrst to assess the association between LPS-stimulated
inﬂammation levels and depression and anxiety. Furthermore,
we were able to compare our ﬁndings for innate cytokine
production capacity with those for basal inﬂammation levels
within the same study sample, although these comparisons have
to be made with caution because of the methodological
differences and differences in type and number of inﬂammatory
markers between these two measures. Our study provides clear
evidence that this novel technique of ex vivo stimulation is useful
in detecting immune dysregulation in depression and anxiety.
Another strong aspect of this study was the possibility to control
for several lifestyle and health factors that were accurately
examined.
In conclusion, lifestyle and health factors may partly explain
higher levels of basal, as well as LPS-stimulated inﬂammation in
persons with depressive and anxiety disorders. However, innate
cytokine production capacity is positively associated with severity
of depressive and in particular anxiety symptoms, even while
taking lifestyle and health factors into account. IL-8 production
capacity might indicate a genetic vulnerability for depressive and
anxiety disorders. Measuring innate immune activity gives
additional insight into the role of the immune system in
depression and anxiety.
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